Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
about
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive reviewSide effects of yttrium-90 radioembolizationTransarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developmentsManagement of hepatocellular carcinoma with portal vein thrombosisA systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosisUnresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spreadRadioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.Chemoembolization and radioembolization for hepatocellular carcinoma.Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy: A retrospective study.Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma.Localized hyperthermia with iron oxide-doped yttrium microparticles: steps toward image-guided thermoradiotherapy in liver cancer.Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma.Current management of hepatocellular carcinoma: an Eastern perspective.A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus.Hepatic imaging following intra-arterial embolotherapy.Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey.New concepts in embolotherapy of HCC.Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages.Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center.A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.Bridging to liver transplantation in HCC patients.Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience.Cytokines and 90Y-Radioembolization: Relation to Liver Function and Overall Survival.Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis.Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysisYttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
P2860
Q26772299-0E09ECCA-BB71-4FBC-8EF7-5CA8B7DF202CQ26821887-FEA4835B-34F5-4351-97D7-43AFEA52B3FCQ26852174-D29A20B5-CEF7-47E3-AF10-10EE1358E8C7Q26996578-998DC9A9-3377-4229-8447-110D90DD3955Q28079066-25D55BF5-73C8-4EE0-9ECB-92B6739A83D1Q30248206-94A57ED2-975B-4C4F-AF93-C00A212A3C57Q33594862-9E0C63A2-B289-431E-9BFB-D6973865A503Q33797067-FD347E33-5E8A-401E-ACA2-CB40737BD453Q34077181-F3CF8976-AE68-4C19-8633-292F4C3B3C1BQ35116226-4461C1A7-602E-4ECE-B352-D321CA748BF9Q35553137-FB87DEC5-BF51-4843-A92D-BD8FB0367538Q36009432-5C246B79-F1CD-4985-8D0A-CC6B30B27433Q37068157-94D80B07-6FA3-4D3E-9319-B111708DC352Q37238192-C3D23B3F-7AE4-42A2-BC5E-5189F2696079Q37396794-7071CB20-F632-4144-BF7C-2E8B96C0D2AFQ37468208-22C69AE0-6A7B-415E-A24D-D123C1B66AFEQ37596678-593F99D2-E4D6-42CA-82BD-A13B949250DFQ37619480-C43E6D8D-5BB6-4FAD-A058-19E5558E2A4DQ38101443-7EEC1DCC-47EB-430E-BAEA-CFED762E7398Q38283656-C33B78D2-74DE-49CA-AC1C-4C5CB5EE5C93Q38410816-829B0448-3C15-4F6B-B4C7-4F3B0CAC1B0FQ38665389-6809A0CF-4FD1-472F-B90F-F19E91B3E3F2Q38716483-ABF46256-741A-4EB9-A219-FF23BA9EA8A6Q38820543-CAC54681-2095-429F-9D38-D6C0BBEA081BQ38822596-47316284-994E-4238-B4EA-57E4B42FAE10Q38904263-EC0BC2D2-105D-4983-A8B0-0EB1A3BF4FDBQ39349638-4E4BB2D1-5E0B-4BD9-8496-EB4A6BE296B6Q40444455-6F9F1FAB-B141-41EA-99F6-24059181026CQ41108851-03E97ED6-8238-4DF4-A30D-B60B7D6D5604Q47440581-7A041BD1-4044-4A98-91AA-35CC59801F94Q48230943-E0E5C6ED-70FC-412B-9A2C-630FF5CD2C03Q48326665-0A164D61-6BDF-4DD5-A49C-56FA5614AAE5Q50125448-C90B37D9-519C-472B-8EA0-7FE9E730DFD5Q50850008-DEFB61C2-E9CF-45BE-BFB3-C665580DBAE4Q53220257-A7D71CC4-6CE9-48BE-B908-BB39973231D4Q53525194-64FDC61C-14E5-4EC9-9CB3-F412491F4566Q56970979-29652CBE-9B17-4CFB-8912-0D2793E942C1Q58804965-156D2956-5C25-48B1-B6D5-E39554EEC218
P2860
Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Radioembolization for hepatoce ...... ptions at disease progression.
@ast
Radioembolization for hepatoce ...... ptions at disease progression.
@en
type
label
Radioembolization for hepatoce ...... ptions at disease progression.
@ast
Radioembolization for hepatoce ...... ptions at disease progression.
@en
prefLabel
Radioembolization for hepatoce ...... ptions at disease progression.
@ast
Radioembolization for hepatoce ...... ptions at disease progression.
@en
P2093
P2860
P50
P1476
Radioembolization for hepatoce ...... options at disease progression
@en
P2093
Al B Benson
Daniel Ganger
Frank H Miller
Khairuddin Memon
Laura Kulik
Mary F Mulcahy
Michael Vouche
Ramona Gupta
Reed A Omary
Robert J Lewandowski
P2860
P356
10.1016/J.JHEP.2012.09.003
P577
2012-09-18T00:00:00Z